GLP-1 Insurance Coverage Changes: What’s New for 2026

Introduction

GLP-1 insurance coverage shifted more in the 2025 to 2026 plan-year transition than in any year since the drugs first launched. Some large employer plans cut weight-loss coverage entirely after their pharmacy spend doubled. Others added coverage for the first time in response to employee demand. CMS expanded Medicare semaglutide access for cardiovascular indications. PBMs rewrote formulary tiers across the board.

The result is a confusing landscape where two coworkers at the same company can have very different coverage depending on which plan they picked at open enrollment.

This article walks through what actually changed for 2026, how to verify your specific coverage, and what to do if your plan dropped or restricted GLP-1 access.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Changed for Medicare GLP-1 Coverage in 2026?

The biggest Medicare change carried over from 2024 to 2025: CMS issued guidance allowing Medicare Part D plans to cover semaglutide (Wegovy®) when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity. That guidance is based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events with semaglutide versus placebo in patients with CVD and overweight or obesity.

Quick Answer: Medicare Part D now covers semaglutide for cardiovascular risk reduction in patients with established CVD and overweight or obesity, following the SELECT trial (Lincoff et al. 2023 NEJM)

For 2026 plans, this coverage is more widely implemented. Most major Medicare Part D plans (UnitedHealthcare, Humana, Aetna, Cigna, Wellcare) have added semaglutide to their formularies for this indication, generally on a higher tier with prior authorization.

Medicare still does not cover GLP-1s for weight loss alone. The 2003 Medicare Modernization Act explicitly excludes coverage for drugs used for weight loss. The Treat and Reduce Obesity Act has been introduced in Congress multiple times since 2013 and remained pending through the 2026 session.

Medicare Advantage plans can offer supplemental weight-loss benefits, and a small number of plans started doing so for 2026, though these benefits are limited.

Which Employer Plans Cut GLP-1 Coverage for 2026?

Several large employer plans reduced or eliminated GLP-1 weight-loss coverage going into 2026. Many cited cost growth and utilization spikes from 2024 to 2025.

The Federal Employees Health Benefits Program negotiated coverage variation across carriers, with some plans tightening BMI cutoffs and prior authorization. Several state employee plans, including North Carolina and West Virginia, limited or eliminated weight-loss GLP-1 coverage in the 2024 to 2025 cycle, and those restrictions largely held into 2026.

Some Fortune 500 employers dropped weight-loss GLP-1 coverage entirely while retaining coverage for diabetes indications. Others added coverage but tightened BMI thresholds, often requiring BMI 35 or higher rather than 30, and adding step therapy through phentermine, naltrexone-bupropion, or behavioral programs first.

The pattern reflects how quickly utilization grew. Some PBM reports showed weight-loss GLP-1 utilization doubling year over year in 2023 to 2024, which drove total pharmacy spending growth that few plans could absorb without changes.

Which PBM Formulary Tiers Changed for 2026?

The three big PBMs (Express Scripts, CVS Caremark, OptumRx) all published 2026 formulary updates affecting GLP-1 placement.

Express Scripts moved Wegovy to a higher specialty tier on its National Preferred Formulary for some plan designs and added prior authorization requirements tied to BMI and prior weight-loss attempts. Zepbound® retained preferred status on most Express Scripts formularies through a coverage agreement with Eli Lilly.

CVS Caremark added Wegovy as a preferred GLP-1 weight-loss option on several major formularies after negotiating with Novo Nordisk, while Zepbound retained coverage on most templates. Step therapy and prior authorization requirements increased.

OptumRx maintained both Wegovy and Zepbound on its Premium formulary with prior authorization. Some employer-specific formularies through OptumRx added stricter BMI cutoffs and step therapy.

The exact placement varies by employer because PBMs offer multiple formulary templates and plans can customize.

Which Insurance Plans Still Cover GLP-1s Without Restrictions in 2026?

True open coverage is rare. Most plans that do cover GLP-1s for weight loss in 2026 have some combination of prior authorization, BMI cutoffs, step therapy, or quantity limits.

The plans with the most permissive 2026 coverage tend to be high-tier employer plans at companies with strong wellness benefits, large tech employers with younger workforces, and some union health plans.

Federal employee plans vary by carrier. Some Blue Cross Blue Shield Federal Employee Program options cover GLP-1s for obesity with prior authorization. Others have stricter requirements.

Medicaid weight-loss GLP-1 coverage expanded in 4 additional states for 2026, bringing the total to roughly 20 states. Coverage typically requires BMI 30 or higher with comorbidities or BMI 35 or higher without.

The Kaiser Family Foundation tracker is the cleanest single source for state-by-state Medicaid coverage.

What Does Prior Authorization Typically Require?

Prior authorization for GLP-1s in 2026 is more rigorous than in 2024. Common requirements:

BMI documentation, usually 30 or higher with a comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease) or 35 or higher without comorbidities. Some plans require BMI 40 or higher.

Documented prior weight-loss attempts, typically 6 to 12 months of diet, exercise, and behavioral intervention with measurable outcomes. Some plans require participation in a structured program.

Step therapy through older agents. Some plans require failure on phentermine, naltrexone-bupropion, orlistat, or topiramate-phentermine before approving a GLP-1.

Lab documentation, often hemoglobin A1c, lipid panel, complete metabolic panel, and TSH within recent months.

Re-authorization at 6 months, typically requiring documented weight loss of at least 5% to continue coverage.

How Much Do GLP-1s Cost with Insurance in 2026?

Out-of-pocket costs vary widely depending on plan design.

For plans with preferred coverage, copays typically run $25 to $100 per month. For specialty tier placement, copays can run $200 to $400 per month, or coinsurance at 20 to 40% of the drug cost.

High-deductible plans require full payment until the deductible is met. With Wegovy and Zepbound list prices around $1,000 to $1,350 monthly, that can mean several months of full-price payment.

Both Novo Nordisk and Eli Lilly offer manufacturer copay savings cards for commercially insured patients. These can reduce out-of-pocket cost to roughly $25 monthly for eligible patients. Government program patients (Medicare, Medicaid, TRICARE) cannot use manufacturer copay cards by federal anti-kickback rules.

Direct-to-consumer cash programs from the manufacturers (NovoCare Pharmacy for Wegovy, LillyDirect for Zepbound) offer vial pricing at $349 to $499 monthly for self-pay patients.

Key Takeaway: Express Scripts, CVS Caremark, and OptumRx all updated formulary placement for tirzepatide and semaglutide for 2026

What If My Plan Denied GLP-1 Coverage?

Several options exist if coverage is denied.

Appeal the denial. Most plans allow at least one level of internal appeal and one external review. Working with your prescribing clinician to document medical necessity often improves results. If the denial reason is failure to meet step therapy, document any prior attempts at older agents.

Pursue manufacturer savings programs. Both Novo Nordisk and Eli Lilly run patient assistance programs for low-income patients with no insurance coverage.

Switch to cash-pay options. Manufacturer DTC vial programs ($349 to $499 monthly) are one option. Compounded semaglutide and tirzepatide through state-licensed 503A pharmacies via telehealth platforms (TrimRx among them) typically run $179 to $499 monthly. TrimRx offers a free assessment quiz to determine clinical eligibility.

Switch plans at open enrollment. If your employer offers multiple plan options, the difference in GLP-1 coverage can be substantial.

Are State Medicaid Programs Expanding GLP-1 Coverage?

Yes, slowly. As of early 2026, roughly 20 state Medicaid programs cover GLP-1s for obesity beyond diabetes, up from 16 in early 2025.

The 2026 expansions added a mix of state-level legislation and Medicaid director decisions. Pennsylvania, Michigan, and Massachusetts expanded coverage in early 2026. Several other states have pending decisions.

Most state Medicaid GLP-1 coverage requires prior authorization with documented BMI, comorbidities, prior weight-loss attempts, and ongoing nutrition or behavioral counseling. Coverage durations are typically 6 to 12 months with re-authorization required.

State Medicaid coverage matters because it disproportionately serves populations with higher obesity prevalence and worse access to alternatives.

How Are Tricare and VA Covering GLP-1s in 2026?

TRICARE covers GLP-1s with prior authorization. Coverage for type 2 diabetes is straightforward. Coverage for obesity requires BMI 30 or higher with comorbidities or BMI 35 or higher without, plus documented prior weight-loss attempts.

The VA covers GLP-1s through its national formulary with prior authorization. Veterans with type 2 diabetes have broad access. Coverage for obesity requires similar BMI and documentation requirements to TRICARE.

Both TRICARE and VA pay government negotiated prices, which are substantially below commercial list prices but not made public.

What About HSA and FSA Spending for GLP-1s?

GLP-1 prescriptions are HSA and FSA eligible when prescribed for a qualifying medical condition (obesity, type 2 diabetes, cardiovascular risk reduction, OSA). The IRS treats them as deductible medical expenses.

That means even if your insurance does not cover the drug, you can use pre-tax HSA or FSA dollars to pay cash for it. For self-pay patients in the 24 to 35% tax bracket, that effectively reduces the cost by 24 to 35%.

HSA and FSA reimbursement applies to brand prescriptions, manufacturer DTC vial programs, and compounded prescriptions through telehealth platforms like TrimRx as long as they are written by a licensed prescriber for a valid medical condition.

A Letter of Medical Necessity from your prescribing clinician helps document HSA or FSA eligibility if the plan administrator questions it.

Bottom line: State Medicaid coverage expanded in 4 additional states for 2026, bringing the total to roughly 20

FAQ

Does Medicare Cover Wegovy in 2026?

Medicare Part D plans can cover semaglutide (Wegovy) for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity, following CMS guidance based on the SELECT trial. Coverage for weight loss alone is still not allowed under federal law.

Why Did My Employer Plan Stop Covering Wegovy for 2026?

Several large employer plans cut weight-loss GLP-1 coverage citing cost growth. PBM reports showed weight-loss GLP-1 utilization roughly doubled year over year in 2023 to 2024, which drove total pharmacy spending up sharply.

What Is the Cheapest Way to Get a GLP-1 in 2026 Without Insurance?

The lowest-cost options for self-pay are compounded semaglutide or tirzepatide through state-licensed 503A pharmacies via telehealth platforms like TrimRx, often $179 to $499 monthly. Manufacturer DTC vial programs (NovoCare for Wegovy, LillyDirect for Zepbound) run $349 to $499 monthly.

What Does Prior Authorization for Zepbound Require?

Common requirements include BMI 30 or higher with comorbidities or BMI 35 or higher without, documented prior weight-loss attempts, lab work, and sometimes step therapy through older agents. Re-authorization at 6 months typically requires at least 5% weight loss.

Can I Use My HSA for GLP-1 Prescriptions?

Yes, GLP-1s prescribed for a qualifying medical condition are HSA and FSA eligible. This applies to brand, manufacturer DTC, and compounded prescriptions. A Letter of Medical Necessity from your prescriber helps document eligibility.

Will More States Add Medicaid GLP-1 Coverage in 2026?

Several states have pending decisions on Medicaid GLP-1 coverage for obesity beyond diabetes. The Kaiser Family Foundation tracker maintains the current state-by-state list.

How Do I Appeal a GLP-1 Coverage Denial?

Most plans allow internal appeal and external review. Work with your prescribing clinician to document medical necessity, BMI, comorbidities, and any prior weight-loss attempts. If denial cites step therapy, document past attempts at older agents.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.